Over 1.8 million nonprofits and charities for donors, volunteers and funders

Claim This Nonprofit

More Info

Add to Favorites

Share this Nonprofit

Donate

Volunteering Oportunities

Nonprofit Overview

Causes: Government & Public Administration, Health, Medical Research, Mental Health, Mental Health Treatment

Mission: Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS furthers its mission by: -Developing psychedelics and marijuana into prescription medicines -Training therapists and working to establish a network of treatment centers -Supporting scientific research into spirituality, creativity, and neuroscience -Educating the public honestly about the risks and benefits of psychedelics and marijuana MAPS envisions a world where psychedelics and marijuana are safely and legally available for beneficial uses, and where research is governed by rigorous scientific evaluation of their risks and benefits.

Results: MAPS has completed two Phase 2 FDA studies using MDMA-assisted psychotherapy to treat PTSD, and is in the process of four other similar studies. MAPS also has a study looking at LSD-assisted psychotherapy for treating end-of-life anxiety, an outcome study of the benefits of ibogaine for opiate dependence, and a protocol to investigate medical marijuana to relieve symptoms of PTSD.

Target demographics: Any person whose life may be aided by the transformative nature of psychedelic psychotherapy

Geographic areas served: Worldwide

Programs: Maps' primary focus is research into mdma-assisted psychotherapy ($1,094,575), especially phase 2 research into mdma-assisted psychotherapy in subjects with chronic, treatment-resistant ptsd. In this fiscal year, maps treated the 18th subject in our charleston, south carolina mdma/ptsd study in 24 veterans, firefighters and police officers. An 8th subject was treated in our study in boulder, colorado for people suffering from ptsd from any source, a fourth subject was treated in our mdma/ptsd study in beer yaakov, israel, and an irb approved the amendments for our mdma/ptsd study in vancouver, canada. A 7th therapist participated in our mdma-assisted psychotherapy therapist training study. In addition to our core clinical research, this fiscal year we began planning a series of studies in collaboration with researchers who work with the u. S. Department of veterans affairs' national center for ptsd. We'll be exploring the use of mdma along with more traditional psychotherapeutic methods for treating ptsd including cognitive-behavioral conjoint therapy, cognitive processing therapy, and prolonged exposure therapy. We also began our study looking at the safety and efficacy of using mdma-assisted therapy for anxiety in adults on the autism spectrum and began preparations for a study of mdma-assisted psychotherapy for end-of-life anxiety. These studies will grow significantly in the coming year. Mdma-study related program expenses include costs of video data storage and streaming systems development, budgeting, contracting, and meetings; the costs of developing the treatment manual; training therapists; blinded therapist adherence training; and costs of reviewing and documenting all published mdma literature. There are also mdma-study related supervision of therapists, presentation of our data at professional conferences, and costs to manage the mdma purchased early in our work and to secure the drug for phase 3 trials expected to begin in 2016. Clinical research general costs cover the development of the infrastructure needed for our mdma clinical trials, including work with communications and fundraising departments, staff professional development and conferences, and video streaming and statistical software. Most of the clinical research expenses are personnel, including personnel at each study site: principal investigators, co-investigators, independent raters, overnight physicians, attendant, and study coordinators, as well as maps' internal staff: the clinical director, research associates, information specials, data coordinators and statistical consultants. Ibogaine research expenses were dedicated to completing our studies in mexico ($3,816), and new zealand ($6,329). Lsd research expenses ($12,185) were primarily used for the march 2014 publication of our lsd end-of-life anxiety article in the journal of nervous and mental disease. Marijuana research ($14,905) covered the costs of developing the protocol for a pilot study in which marijuana will be tested to manage symptoms in 76 veterans with chronic, treatment-resistant ptsd, and our efforts to end the public health service (phs) review and the national institute of drug abuse (nida) monopoly of the sale of marijuana for clinical research.

education expenses include harm reduction, events, publications and communications programs. Our zendo project provides a supportive space for people undergoing difficult psychedelic experiences in order to help turn those experiences into opportunities for learning and personal growth, and to reduce the number of drug-related psychiatric hospitalizations and arrests. Services were provided at five major events in fiscal year 2014: burning man (black rock city, nv), envision (costa rica), afrikaburn (south africa), bicycle day (san francisco, ca), and lightning in a bottle (bradley, ca). In order to share recent findings and to inspire existing and new support, maps produced events on psychedelic and marijuana research in colorado, vancouver and santa cruz; and attended more than 17 events that others produced, providing speakers, exhibits, sales of books and maps bulletins, and free distribution of clinical protocols and articles from peer-reviewed journals. Communications included publishing three maps bulletins, and 12 email newsletters, maintaining maps. Org, mdmaptsd. Org, mapscanada. Org, psychedelicscience. Org, and launching mdma-autism. Org. Maps produced "manifesting minds," with north atlantic books, reprinted albert hofmann's "lsd: my problem child," and began work with stanislav grof on his new book, "the visionary world of h. R. Giger. " in spring 2014, maps offered its first webinar, "psychedelic science," in collaboration with evolver learning labs. Maps saw significant growth in coverage of its work in social, online, and traditional media. Maps. Org had 511,449 unique visits and 1,809,246 page views. Facebook likes more than doubled to 89,282. Twitter followers increased 140%, to 17,099. Youtube subscriptions increased 256% to 5,313. Maps received 344 unique media mentions from online and print publications with significant reach. Media outlets include the los angeles times, the new york times, the san francisco chronicle, reason, scientific american, cnn, usa today, msnbc, time, associated press, fox news, forbes, nbc news, playboy, santa cruz sentinel, tricycle, business insider, npr, vice, and southern california public radio (kpcc).

this year, maps operationalized its long-running fiscal sponsorship program, clarifying and updating contracts, process, and structure. This program supports projects that are in alignment with maps mission and vision by offering donors a way to give to a 501(c) 3 nonprofit organization. Maps monitors the project budget, takes a small fee, and sends the donor a receipt for their contribution.

Community Stories

111 Stories from Volunteers, Donors & Supporters

4

Volunteer

Rating: 5

MAPS has worked for years to get psychedelics the fair consideration they deserve. These are tools that have many powerful psychological/psychiatric potentials that are just beginning to be discovered. This organization does tremendous work educating the public and representatives, and also funding and supporting clinical trials.

Review from Guidestar

4

Volunteer

Rating: 5

Great team of people who pulled off an incredible conference - first scientific review of psychedelic science in 17 years. I connected with thought leaders and medical professionals with a shared vision treatment, and got to review the evidence for areas of research that are loaded with potential. My career track has shifted, towards a new and positive direction as a result of the conference.

Review from Guidestar

7

Volunteer

Rating: 5

If our species and small world is to last much longer we better support positive change for our environment and consciousness.For decades MAPS has taken the lead in destigmatizing psychoactive medicines and supporting research to further understand their practical uses, with ongoing and increasing success.

Review from Guidestar

6

Volunteer

Rating: 5

MAPS means a lot of things to a wide variety of people. While their mission statement (to develop psychedelics into therapeutic aids) is indeed a noble and legitimate cause, the organization represents a whole lot more and inspires people far beyond its expressed cause. They give voice to and unite a community of scientists, artists, and spiritualists who are all inspired by psychedelics in some way or another, and I personally feel that MAPS challenges this community to articulate the many beneficial uses of psychedelics. They offer hope that psychedelics can not only be used to improve the world around us, but that the society we live in is also responsive to psychedelics as a vessel for change.

Review from Guidestar

10

Volunteer

Rating: 5

MAPS is a very important organization for the progress of humanity on earth in our current age. The scientific study of consciousness altering compounds is at the forefront of human scientific knowledge and significance for the development of human society, civilization and individuals, as well as for the health of the planet. This organization is effectively neutralizing harmful stigmas which prevent positive progress in the area of human psychology and spirituality. Psychedelics are a key issue for all people and must be dealt with in a mature, respectable, and interdisciplinary fashion. MAPS is guiding the vision of a positive and healthy relationship with these powerful medicines and should be commended for their courage, relevance, and maturity.

Review from Guidestar

9

Volunteer

Rating: 5

MAPS is a wonderful organization that should be part of every medical research center. The mind is the most powerful portion of a human, why wouldn’t we be doing everything possible to unlock the mysteries of that extraordinary part of existence. Psychedelics are the catalyst that clarifies consciousness thinking. Done in a proper setting, the psychedelic experience will be life changing in a positive way while rising up awareness and understanding of life’s natural path to harmony. I know that consciousness expansion is a must, and should be at the top subject of the media, government, churches, schools, and in the community. Let’s keep supporting MAPS and other foundations like it to keep doing all the beautiful research and putting these psychedelics in the main stream. If everyone could understand the medical and life enhancement implications of these substances, it shouldn’t be too hard to get them to the public………….RIGHT ! Once the media, government, churches, schools, and community start educating and putting psychedelics on the top priority list then we can see massive change in this world. Thank you MAPS for getting us closer and closer every day.

Review from Guidestar

8 kymerikal

Volunteer

Rating: 5

it's pretty clear that we can't rely on Big Pharma to design safe medicines that work--lying about results, cheating on FDA approvals, making drugs with side effects worse than the disease--so MAPS is stepping up to do so. the fact that the clinical trials and conferences they designs, funds, and otherwise supports are on drugs that have been the subject of cultural and political repression for years only compounds the importance of what they're doing. MAPS has the technical know-how, the political savvy, and the guts to change how medicine is made.

Review from Guidestar

10

Volunteer

Rating: 5

MAPS continues to be a vital interphase between mind and body, between society and it's future, between spirit and matter and between relief and pain between fear of death and embracing peace for patients who need the services that psychedelic substances can produce in the proper set and setting.

Review from Guidestar

Previous Stories
8

Volunteer

Rating: 5

MAPS continues to be a vital interphase between mind and body, between society and it's future, between spirit and matter and between relief and pain for patients who need the services that psychedelic substances can produce in the proper set and setting.

Review from Guidestar

11

Volunteer

Rating: 5

I've always been interested in alternative ways to raise people's consciousness as well as being able to heal them through psychedelic modalities. The work that was started years ago in the psychedelic field, has now reached a new plateau with MAPS. Rick and company have expertly and responsibly paved the way to opening new vistas through the continuing research, medical applications, and awareness of psychedelics.

Review from Guidestar

10

Volunteer

Rating: 5

Just at the moment i sit at my Mac, at home in Switzerland/Bern writing a homework for my study in Psychotherapy about PTSD-therapy. Because there is also one MDMA/PTSD Study in Switzerland sponsored by maps, i use this site for getting all my information i need. I honour the work of MAPS for their enthusiasm and professionality in proceeding all the work which is needed to become psychoactives useful and legal medicine. In my profession as therapist i see many people suffering on their illnesses not finding a way to their inner being. I think, MDMA used in a professional kind of therapy is a powerful instrument for finding out of a problem related world into a self regulated one by recognizing one's own responsibility. And this by a way no other regular psychopharmaka supported therapy can afford.

Review from Guidestar